Form 4: Bicycle Therapeutics Director Receives Equity Awards

Bicycle Therapeutics PLC Director Herve Hoppenot was granted 12,500 restricted share units and options for 25,000 ordinary shares.

Summary

• Herve Hoppenot, a Director of Bicycle Therapeutics PLC (BCYC), was granted equity awards on September 8, 2025.
• The awards include 12,500 Restricted Share Units (RSUs), each representing a contingent right to receive one ordinary share.
• These RSUs will vest in three equal installments on September 8, 2026, September 8, 2027, and September 8, 2028.
• Additionally, Mr. Hoppenot received stock options to purchase 25,000 ordinary shares at an exercise price of $7.16 per share.
• These stock options also vest in three equal installments on September 8, 2026, September 8, 2027, and September 8, 2028, and expire on September 8, 2035.

Sentiment

Score: 7

Explanation: The equity awards to a director align management interests with shareholders, which is generally viewed positively, though it's a routine compensation event rather than a strategic operational update.

Positives

• The granting of equity awards to a director aligns their interests with those of the shareholders, promoting long-term value creation.
• The multi-year vesting schedule encourages sustained commitment and performance from the director.

Future Outlook

The vesting schedules for the restricted share units and stock options extend through September 2028, indicating a continued alignment of the director's incentives with the company's long-term performance.

Industry Context

Equity awards, such as restricted share units and stock options, are a standard component of executive and director compensation packages in the biotechnology industry, designed to attract and retain talent while aligning their interests with shareholder value.

Comparison to Industry Standards

• The structure of equity awards, including restricted share units and stock options with multi-year vesting, is a common practice for director compensation in the biotechnology industry.
• Specific benchmarking against peer companies would require detailed compensation data not present in this filing.

Related Party Transactions

• The equity awards to Herve Hoppenot, a Director of Bicycle Therapeutics PLC, constitute a related party transaction as it involves compensation to a member of the company's management.

Stakeholder Impact

• Shareholders: Benefit from increased alignment of the director's financial interests with the company's long-term performance.
• Employees: No direct impact mentioned, but executive compensation practices can influence overall company culture and morale.

Next Steps

• Vesting of 12,500 Restricted Share Units in three equal installments on September 8, 2026, September 8, 2027, and September 8, 2028.
• Vesting of options for 25,000 ordinary shares in three equal installments on September 8, 2026, September 8, 2027, and September 8, 2028.
• Potential exercise of stock options by the director at the exercise price of $7.16 per share, anytime between vesting and the expiration date of September 8, 2035.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a director, which is a standard practice to align management incentives with shareholder interests. It does not provide new operational or financial information that would warrant a change in investment recommendation based solely on this disclosure.

Keywords

Bicycle Therapeutics, BCYC, Herve Hoppenot, Form 4, SEC filing, Restricted Share Units, Stock Options, Equity Award, Director Compensation, Insider Trading Report